NEWTON, Mass.--(BUSINESS WIRE)--Aug. 17, 2006--Clinical Data, Inc. Exercises Right to Manufacture Vilazodone Under License Agreement with Merck KGaA of Darmstadt, Germany Meets With FDA to Review Vilazodone Program and Manufacturing Plans Clinical Data, Inc. (NASDAQ: CLDA) announced that over 150 patients have now been enrolled in the Company’s Phase 3 clinical study of vilazodone for the treatment of depression. The trial is being conducted as a double-blind, placebo-controlled study designed to assess the safety and efficacy of vilazodone for the treatment of depression. The trial will enroll approximately 400 adult patients diagnosed with Major Depressive Disorder at nine U.S. centers. As part of the trial, Clinical Data will also seek to discover genetic markers for response to vilazodone.
